Table 2.

Cox regression analysis between body roundness index (BRI) and all-cause mortality and cardiovascular mortality

	Model I			Model II			Model III
	HR	95 % CI	P-value	HR	95 % CI	P-value	HR	95 % CI	P-value
All-cause mortality
As categorical variables (quartile)
Q1	Reference			Reference			Reference
Q2	1·72	1·57, 1·89	<0·001	0·80	0·73, 0·88	<0·001	0·83	0·75, 0·92	<0·001
Q3	2·18	1·99, 2·39	<0·001	0·76	0·70, 0·84	<0·001	0·73	0·65, 0·81	<0·001
Q4	2·46	2·25, 2·69	<0·001	0·90	0·82, 0·99	0·0288	0·80	0·72, 0·89	<0·001
P for trend	<0·001			0·3918			<0·001
CVD mortality
As categorical variables (quartile)
Q1	Reference			Reference			Reference
Q2	2·05	1·64, 2·57	<0·001	0·86	0·69, 1·08	0·203	0·79	0·62, 1·00	0·0548
Q3	3·17	2·56, 3·92	<0·001	0·98	0·79, 1·22	0·8585	0·78	0·62, 0·99	0·0387
Q4	3·22	2·60, 3·98	<0·001	1·09	0·88, 1·35	0·4501	0·79	0·62, 1·01	0·0629
P for trend	<0·001			0·0659			0·2122

Data were showed by HR, 95 % CI and P value.

Q1:0·68∼3·58, Q2:3·59∼4·87, Q3:4·88∼6·38, Q4:6·39∼23·48.

Model I adjusted for none.

Model II adjusted for age, gender and race.

Model III adjusted for age, gender, race, smoking, systolic blood pressure (SBP), diastolic blood pressure (DBP), estimated glomerular filtration rate (eGFR), HDL, total cholesterol (TC), CVD, hypertension, diabetes, lipid-lowering drugs, antihypertensive drugs andhypoglycaemic agents, antiplatelet drugs.